Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel

Urology

Volumn 78, Issue 5, 2011, Pages 1131-1135

  Ito, Masaya ^a   Saito, Kazutaka ^a   Yasuda, Yosuke ^a   Sukegawa, Gen ^a   Kubo, Yuichi ^a   Numao, Noboru ^a   Kitsukawa, Shinichi ^a   Urakami, Shinji ^a   Yuasa, Takeshi ^a   Yamamoto, Shinya ^a   Yonese, Junji ^a   Fukui, Iwao ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; DOCETAXEL; ESTROGEN; HEMOGLOBIN; ZOLEDRONIC ACID;

AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ASSESSMENT; CORTICOSTEROID THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PAIN THRESHOLD; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; SURVIVAL TIME;

AGED; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TREATMENT FAILURE;

EID: 80455135119     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2011.07.1416     Document Type: Article

References (27)

1. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
2. D.R. Berthold, G.R. Pond, and F. Soban Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2008 242 245
3. S. Halabi, N.J. Vogelzang, and A.B. Kornblith Pain predicts overall survival in men with metastatic castration-refractory prostate cancer J Clin Oncol 26 2008 2544 2549
4. S. Halabi, E.J. Small, and P.W. Kantoff Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer J Clin Oncol 21 2003 1232 1237 (Pubitemid 46606398)
5. O. Smaletz, H.I. Scher, and E.J. Small Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration J Clin Oncol 20 2002 3972 3982
6. A.J. Armstrong, E.S. Garrett-Mayer, and Y.C. Yang A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis Clin Cancer Res 13 2007 6396 6403 (Pubitemid 350075029)
7. A.J. Armstrong, I.F. Tannock, and R. de Wit The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival Eur J Cancer 46 2010 517 525
8. A.J. Armstrong, E. Garrett-Mayer, and R. de Wit Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer Clin Cancer Res 16 2010 203 211
9. D.C. McMillan, K. Canna, and C.S. McArdle Systemic inflammatory response predicts survival following curative resection of colorectal cancer Br J Surg 90 2003 215 219 (Pubitemid 36237897)
10. S.D. Heys, K.N. Ogston, and W.G. Simpson Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: response and survival Int J Oncol 13 1998 589 594 (Pubitemid 28372686)
11. P. Guillem, and J.P. Triboulet Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer Dis Esophagus 18 2005 146 150 (Pubitemid 41801107)
12. K. Saito, M. Tatokoro, and Y. Fujii Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma Eur Urol 55 2009 1145 1153
13. K. Saito, S. Kawakami, and Y. Ohtsuka The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically BJU Int 100 2007 269 273 (Pubitemid 47036572)
14. S. Yoshida, K. Saito, and F. Koga C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy BJU Int 101 2008 978 981 (Pubitemid 351422558)
15. T.M. Beer, A.S. Lalani, and S. Lee C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial Cancer 112 2008 2377 2383
16. R.C. Prins, B.L. Rademacher, and S. Mongoue-Tchokote C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results Urol Oncol 2010 Mar. 5
17. Y. Iimura, K. Saito, and Y. Fujii Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score J Urol 181 2009 1004 1012
18. F.A. Mahmoud, and N.I. Rivera The role of C-reactive protein as a prognostic indicator in advanced cancer Curr Oncol Rep 4 2002 250 255
19. J.J. Caro, M. Salas, and A. Ward Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review Cancer 91 2001 2214 2221 (Pubitemid 32552805)
20. C. Nieder, E. Haukland, and A. Pawinski Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases BMC Cancer 10 2010 284
21. A. Macci, C. Madeddu, and D. Massa Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia Blood 106 2005 362 367 (Pubitemid 40967214)
22. K. Mori, K. Fujimoto-Ouchi, and E. Onuma Novel models of cancer-related anemia in mice inoculated with IL-6-producing tumor cells Biomed Res 30 2009 47 51
23. M.L. Jacober, R.L. Mamoni, and C.S. Lima Anaemia in patients with cancer: role of inflammatory activity on iron metabolism and severity of anaemia Med Oncol 24 2007 323 329 (Pubitemid 350135955)
24. J.Y. Chun, N. Nadiminty, and S. Dutt Interleukin-6 regulates androgen synthesis in prostate cancer cells Clin Cancer Res 15 2009 4815 4822
25. Z. Culig, H. Steiner, and G. Bartsch Interleukin-6 regulation of prostate cancer cell growth J Cell Biochem 95 2005 497 505 (Pubitemid 41420180)
26. C. García-Moreno, C. Méndez-Dávila, and C. de la Piedra Human prostatic carcinoma cells produce an increase in the synthesis of interleukin-6 by human osteoblasts Prostate 50 2002 241 246 (Pubitemid 34184663)
27. H. Steiner, S. Godoy-Tundidor, and H. Rogatsch Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway Am J Pathol 162 2003 655 663 (Pubitemid 36267872)